BackgroundMirvetuximab Soravtansine (MIRV) is a promising antibody‒drug conjugate (ADC) that targets folate receptor alpha (FRα), which is overexpressed in several types of solid tumors. In November 2
HER2 HBCx-5 fragment were engrafted into SHO mice. 35 days later, tumor-bearing mice were treated once weekly for eight consecutive weeks, with 0.05 mg/kg MICAB1 PBD1G-ADCs or IC-PDB1G. Tumor growth w
HER2 HBCx-5 fragment were engrafted into SHO mice. 35 days later, tumor-bearing mice were treated once weekly for eight consecutive weeks, with 0.05 mg/kg MICAB1 PBD1G-ADCs or IC-PDB1G. Tumor growth w
